Zydus Cadila’s Sitagliptin base tablets receives Tentative Approval from FDA
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies including small molecule drugs, biologic therapeutics, and vaccines. The group employs 23000 people worldwide and is dedicated to creating healthier communities globally.